Concepedia

Publication | Closed Access

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

DOI

131

Citations

28

References

2016

Year

Agnieszka Korfel, Uwe Schlegel, Ulrich Herrlinger, Martin Dreyling, Christian Schmidt, L. von Baumgarten, Antonio Pezzutto, Thomas Grobosch, Sied Kebir, Eckhard Thiel,
Journal of Clinical Oncology

Abstract

Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.

References

YearCitations

Page 1